Blake O Langley1,2, Jennifer Joan Ryan1, John Phipps1, Lita Buttolph1, Brenna Bray1, Joseph E Aslan3, Thomas O Metz4, Jan F Stevens5, Ryan Bradley6,7. 1. Helfgott Research Institute, National University of Natural Medicine (NUNM), 2220 SW 1st Ave, Portland, OR, 97201, USA. 2. School of Nursing, University of Washington, 1959 NE Pacific St, Seattle, WA, 98195, USA. 3. School of Medicine, Oregon Health and Science University, 3303 S Bond Ave, Portland, OR, 97239, USA. 4. Biological Sciences Division, Pacific Northwest National Laboratory, 902 Battelle Blvd, Richland, WA, 99354, USA. 5. College of Pharmacy and the Linus Pauling Institute, Oregon State University, 1601 SW Jefferson Way, Corvallis, OR, 97331, USA. 6. Helfgott Research Institute, National University of Natural Medicine (NUNM), 2220 SW 1st Ave, Portland, OR, 97201, USA. rbradley@nunm.edu. 7. Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, 9500 Gilman Dr, La Jolla, CA, 92093, USA. rbradley@nunm.edu.
Abstract
BACKGROUND: Xanthohumol (XN), a bioactive flavonoid from Humulus lupulus with anti-inflammatory properties, has potential benefits for patients with Crohn's disease (CD), a type of inflammatory bowel disease. We recently completed and published results of a placebo-controlled phase I clinical trial demonstrating the safety and tolerability of 24 mg XN daily for 8 weeks. The present study aims to evaluate the safety and tolerability of the same dose of XN adults with clinically active CD in a placebo-controlled phase II clinical trial. Additional aims will assess the impact of XN on inflammatory biomarkers, platelet function, CD clinical activity, and stool microbial composition. The metabolism of XN will also be evaluated. This article provides a model protocol for consideration in investigations of XN or other natural products in disease states. METHODS: A triple-masked, randomized, placebo-controlled trial will be conducted in adults with clinically active CD. Participants (n ≤ 32) will be randomized to either 24 mg encapsulated XN per day or placebo and followed for 8 weeks. Throughout the trial, participants will be queried for adverse events. Biomarkers of clinical safety, blood and stool markers of inflammation, platelet function, Crohn's Disease Activity Index score, stool microbial composition, and XN metabolite profiles in blood, urine, and stool will be assessed every 2 weeks. DISCUSSION: We describe the protocol for a phase II clinical trial that evaluates the safety and tolerability of XN in adults with active CD, as well as evaluate metabolism and mechanisms that are relevant to CD and other diseases with underlying inflammation and/or gut permeability. The effects of XN on inflammatory biomarkers, platelet function, the microbiota, and multi-omics biomarkers measured in this phase II trial of adults with CD will be compared to the effects of XN in healthy adults in our previous phase I trial. The results of the study will advance the evidence guiding the use of XN in patients with CD. TRIAL REGISTRATION: ClinialTrials.gov NCT04590508. Registered on October 19, 2020.
BACKGROUND: Xanthohumol (XN), a bioactive flavonoid from Humulus lupulus with anti-inflammatory properties, has potential benefits for patients with Crohn's disease (CD), a type of inflammatory bowel disease. We recently completed and published results of a placebo-controlled phase I clinical trial demonstrating the safety and tolerability of 24 mg XN daily for 8 weeks. The present study aims to evaluate the safety and tolerability of the same dose of XN adults with clinically active CD in a placebo-controlled phase II clinical trial. Additional aims will assess the impact of XN on inflammatory biomarkers, platelet function, CD clinical activity, and stool microbial composition. The metabolism of XN will also be evaluated. This article provides a model protocol for consideration in investigations of XN or other natural products in disease states. METHODS: A triple-masked, randomized, placebo-controlled trial will be conducted in adults with clinically active CD. Participants (n ≤ 32) will be randomized to either 24 mg encapsulated XN per day or placebo and followed for 8 weeks. Throughout the trial, participants will be queried for adverse events. Biomarkers of clinical safety, blood and stool markers of inflammation, platelet function, Crohn's Disease Activity Index score, stool microbial composition, and XN metabolite profiles in blood, urine, and stool will be assessed every 2 weeks. DISCUSSION: We describe the protocol for a phase II clinical trial that evaluates the safety and tolerability of XN in adults with active CD, as well as evaluate metabolism and mechanisms that are relevant to CD and other diseases with underlying inflammation and/or gut permeability. The effects of XN on inflammatory biomarkers, platelet function, the microbiota, and multi-omics biomarkers measured in this phase II trial of adults with CD will be compared to the effects of XN in healthy adults in our previous phase I trial. The results of the study will advance the evidence guiding the use of XN in patients with CD. TRIAL REGISTRATION: ClinialTrials.gov NCT04590508. Registered on October 19, 2020.
Authors: James D Lewis; Paul Rutgeerts; Brian G Feagan; Geert D'haens; Silvio Danese; Jean-Frederic Colombel; Walter Reinisch; David T Rubin; Christian Selinger; Meenakshi Bewtra; Lisa Barcomb; Ana P Lacerda; Kori Wallace; James W Butler; Meijing Wu; Qian Zhou; Xiaomei Liao; William J Sandborn Journal: Inflamm Bowel Dis Date: 2019-10-23 Impact factor: 5.325
Authors: LeeCole Legette; Chanida Karnpracha; Ralph L Reed; Jaewoo Choi; Gerd Bobe; J Mark Christensen; Rosita Rodriguez-Proteau; Jonathan Q Purnell; Jan F Stevens Journal: Mol Nutr Food Res Date: 2013-08-27 Impact factor: 5.914
Authors: John A Bouranis; Laura M Beaver; Jaewoo Choi; Carmen P Wong; Duo Jiang; Thomas J Sharpton; Jan F Stevens; Emily Ho Journal: Nutrients Date: 2021-08-28 Impact factor: 5.717